ADARx Pharmaceuticals
PrivateLast Round
Corporate Funding
May 14, 2025
Total Funding Raised
$331.5M
Momentum Score
25 /100
Company Overview
ADARx Pharmaceuticals is a biotechnology company focused on developing innovative therapeutics through a proprietary ribonucleic acid targeting platform and advanced delivery technologies to address a variety of diseases, including genetic and central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ADARx Pharmaceuticals Comps
Public and private peers based on sector, stage, and business model.
ADARx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | May 14, 2025 | ||||
| Series C | Aug 9, 2023 | ||||
| Series B Extension | Jan 20, 2023 | ||||
| Series B | Sep 8, 2021 | ||||
| Series A | Nov 4, 2020 |
Key People
Founding team and executive leadership
ADARx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C |
| Sirona Capital | Series B, Series B Extension |
| Bain Capital Life Sciences | Series C |
| TCG Crossover | Series C |
| OrbiMed | Series B Extension, Series C, Series A, Series B |
| Commodore Capital | Series C |
| Invus Opportunities | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 24, 2026
Ryan Fisk appointed as Chief Financial Officer and Chief Business Officer.
- Feb 5, 2026
Donald Fong, MD, appointed as new Chief Medical Officer.
ADARx Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ADARx Pharmaceuticals's valuation, stock price, and market status.
